[Swiss simvastatin multicenter study: 1. Efficacy of 10 mg simvastatin daily in patients with primary hypercholesterolemia].
In a Swiss multicenter study with determination of lipid and lipoprotein parameters in a central laboratory, the efficacy of simvastatin, MSD, was evaluated in patients with primary hypercholesterolemia. Lipid and lipoprotein values were determined in 109 patients before and after 6 weeks' therapy with 10 mg simvastatin per day. A significant decrease in total cholesterol, LDL-cholesterol and apo B, of 21.1, 25.8 and 24.1% respectively, was observed. No influence of simvastatin on apo A-II was found, but HDL-cholesterol and apo A-I were slightly increased (+6.1 and 4.4% respectively). The data show that HMG-CoA reductase inhibitors constitute a new class of effective drugs for the treatment of hypercholesterolemia.
Riesen
W F
WF
Lipidlabor der Universität Bern.
Keller
U
U
Del Bufalo
A
A
Reutter
F W
FW
Baur
H R
HR
Golay
A
A
Bertel
O
O
Kummer
H
H
Kistler
H
H
Ammann
F
F
D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001053:Apolipoproteins / Q000097:blood; D002784:Cholesterol / Q000097:blood; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy*; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D008148:Lovastatin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D019821:Simvastatin; D016037:Single-Blind Method; D013557:Switzerland
D000924:Anticholesteremic Agents; D001053:Apolipoproteins; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids; D008074:Lipoproteins; D002784:Cholesterol; D008148:Lovastatin; D019821:Simvastatin
Schweizerische Simvastatin-Multizenter-Studie: 1. Wirksamkeit von 10 mg Simvastatin pro Tag bei Patienten mit primärer Hypercholesterinämie.